In a climate of increasing tolerance the number of marijuana formulas and extracts being brought to market has exploded, opening the door to challenges from patent-holders.

In October, the U.S. government issued Axim Biotechnologies Inc a patent for a cannabis-based suppository to treat irritable bowel syndrome.

Britain’s GW Pharmaceuticals Plc, which recently brought to market a drug derived from marijuana for epilepsy, is now seeking patent protection for another one to treat eczema.

With marijuana now fully legal in Canada and at least partially legalized in the majority of U.S. states, companies are rushing to patent new formulations of the age-old botanical.

Click here to read the complete article

Jan Wolfe ~ Reuters

Recent News Articles

Tuesday May 21

Poll: Most of Illinois says marijuana should be legal - Cannabis News

in Politics

by Bruce Kennedy - Editor in Chief

A new poll by Global Strategy Group on behalf of Think Big Illinois, says a…

929 hits

Tuesday May 21

New Report Says US Cannabis Market Could Hit $22.7B By 2023 - Cannabis News

in Finance

by Bruce Kennedy - Editor in Chief

A new report projects the cannabis market in the United States will reach $22.7 billion…

1100 hits

Tuesday May 21

We May Finally Know Where the Cannabis Plant Originated - Cannabis News

in Science

by Bruce Kennedy - Editor in Chief

Cannabis may have originated high on the Tibetan Plateau, according to an analysis of fossil…

1332 hits

Tuesday May 21

NFL, NFLPA will reportedly study marijuana as potential pain-management tool for players - Cannabis News

in Sports

by Bruce Kennedy - Editor in Chief

With talks of a new collective bargaining agreement underway, the NFL and NFL Players Association…

1385 hits

Wednesday May 22

Marijuana sales east of Mississippi poised to rival western markets - Cannabis News

in Finance

by Bruce Kennedy - Editor in Chief

The cannabis industry in the United States has long been centered around such states as…

1063 hits